Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampin and Pyrazinamide for Latent Tuberculosis Infection | Zendy

Kashef Ijaz | Zendy; John Jereb | Zendy; Laura Lambert | Zendy; William A. Bower | Zendy; Philip R. Spradling | Zendy; Peter D. McElroy | Zendy; Michael F. Iademarco | Zendy; Thomas R. Navin | Zendy; Kenneth G. Castro | Zendy

Open Access

Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampin and Pyrazinamide for Latent Tuberculosis Infection

Author(s) -

Kashef Ijaz,

John Jereb,

Laura Lambert,

William A. Bower,

Philip R. Spradling,

Peter D. McElroy,

Michael F. Iademarco,

Thomas R. Navin,

Kenneth G. Castro

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/499244

Subject(s) - medicine , pyrazinamide , tuberculosis , liver injury , regimen , gastroenterology , liver disease , latent tuberculosis , serology , hepatitis , surgery , isoniazid , immunology , antibody , mycobacterium tuberculosis , pathology

Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculosis infection. Implicating RZ as the likeliest cause required excluding alternative causes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research